Select Language
VEGF R3
VEGF R3 Overview
| English Name | Vascular endothelial growth factor receptor 3 | Approved Drugs | 13 |
| Drugs in Clinical Trials | 18 | Target Synonym | LMPHM1，Primary Congenital Lymphedema，Fms Related Receptor Tyrosine Kinase 4，VEGF Receptor-3，Feline McDonough Sarcoma (FMS)-Like Tyrosine Kinase 4，VEGFR3，VEGFR-3，FLT4，Vascular endothelial growth factor receptor 3，Fms Related Tyrosine Kinase 4，Tyrosine-Protein Kinase Receptor FLT4，Fms-Like Tyrosine Kinase 4，FLT-4，Fms-Related Tyrosine Kinase 4，LMPH1A，FLT41，PCL，Vascular Endothelial Growth Factor Receptor-3，CHTD7 |
| Highest Development Stage | Approved | ||
| English Name | Vascular endothelial growth factor receptor 3 |
| Target Synonym | LMPHM1，Primary Congenital Lymphedema，Fms Related Receptor Tyrosine Kinase 4，VEGF Receptor-3，Feline McDonough Sarcoma (FMS)-Like Tyrosine Kinase 4，VEGFR3，VEGFR-3，FLT4，Vascular endothelial growth factor receptor 3，Fms Related Tyrosine Kinase 4，Tyrosine-Protein Kinase Receptor FLT4，Fms-Like Tyrosine Kinase 4，FLT-4，Fms-Related Tyrosine Kinase 4，LMPH1A，FLT41，PCL，Vascular Endothelial Growth Factor Receptor-3，CHTD7 |
| Approved Drugs | 13 |
| Drugs in Clinical Trials | 18 |
| Highest Development Stage | Approved |
VEGF R3 Product List
- Product Category
Protein (4)
- Product Status
Launched (4)
- Species
Human (3)Mouse (1)
- Tag
Fc Tag (1)His Tag & Avi Tag (1)Mouse IgG Fc Tag (1)His Tag (1)
- Conjugate
Unconjugated (3)Biotin-labeled (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT FL4-H5251 |  Human | HEK293 | Human VEGF R3 / FLT4 Protein, Fc Tag (MALS verified) |  |  |  |
FL4-H52H3 | Human | HEK293 | Human VEGF R3 / FLT4 Protein, His Tag (MALS verified) |  | | |
FL4-H82E1 | Human | HEK293 | Biotinylated Human VEGF R3 / FLT4 Protein, His,Avitag™ |  | | |
FL4-M5251 |  Mouse | HEK293 | Mouse VEGF R3 / FLT4 Protein, Mouse IgG2a Fc Tag, low endotoxin |  | | |
Total: 4
- 1
VEGF R3 Background
Vascular endothelial growth factor receptor 3 (VEGF R3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). VEGF R3 mediates lymphangiogenesis in response to VEGF-C and VEGF-D. VEGF R3 is widely expressed in the early embryo but becomes restricted to lymphatic endothelia at later stages of development. It is likely that VEGF R3 may be important for lymph angiogenesis.
VEGF R3 Synonyms
Flt-4,FLT4,LMPH1A,PCLFLT41,VEGFR3,VEGFR-3,FLT-4,FLT-41,FLT41,PCL
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Cediranib | AZD2171; AZD-2171; NSC-732208 | Phase 3 Clinical | Astrazeneca Plc | Solid tumours; Ovarian Neoplasms; Leiomyosarcoma; Leukemia; Liver Neoplasms; Optic Nerve Glioma; Skin Melanoma; Head and Neck Neoplasms; Biliary Tract Neoplasms; Medulloblastoma; Lymphoma, B-Cell, Marginal Zone; Ependymoma; Lymphoma, B-Cell; Lymphoma, T-Cell, Peripheral; Carcinoma, Renal Cell; Carcinoma; Spinal Cord Neoplasms; Stomach Neoplasms; Rectal Neoplasms; Leukemia, Hairy Cell; Rhabdoid Tumor; Squamous Cell Carcinoma of Head and Neck; Cystadenoma, Serous; Cystadenocarcinoma, Serous; Cystadenocarcinoma, Mucinous; Glioblastoma; Carcinoma, Transitional Cell; Neoplasms; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Leukemia-Lymphoma, Adult T-Cell; Hormone-Resistant Prostate Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Colonic Neoplasms; Carcinoma, Verrucous; Nasopharyngeal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Hypopharyngeal Neoplasms; Hodgkin Disease; Myelodysplastic Syndromes; Lymphoma, Large-Cell, Immunoblastic; Salivary Gland Neoplasms; Lymphomatoid Granulomatosi | Details |
| Sitravatinib | MGCD-516; IND-155305; MGCD-0516; MG-91516; MG-516 | Phase 3 Clinical | Mirati Therapeutics Inc | Breast Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Endometrial Neoplasms; Lung Neoplasms; Metastatic breast cancer; Mouth Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Hepatic Insufficiency; Ureteral Neoplasms; Solid tumours; Lung Diseases; Liposarcoma; Uveal melanoma; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Carcinoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Kidney Neoplasms; Biliary Tract Neoplasms | Details |
| Axitinib intravitreal implant (Ocular Therapeutix) | OTX-TKI | Phase 3 Clinical | Ocular Therapeutix Inc | Wet Macular Degeneration; Macular Degeneration; Diabetic Retinopathy | Details |
| AUR-109 | ODM-203; AUR-109 | Phase 2 Clinical | Orion Corp | Ovarian Neoplasms; Liver Neoplasms; Kidney Neoplasms; Solid tumours; Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Pulmonary Fibrosis; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms | Details |
| Lucitanib | S-80881; AL-3810; CO-3810; E-3810; S-80881-2 | Phase 2 Clinical | Advenchen Laboratories Nanjing Ltd | Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Nasopharyngeal Carcinoma; Genital Neoplasms, Female; Colorectal Neoplasms; Thymus Neoplasms; Lung Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| Telatinib | EOC-315; BAY-57-9352 | Phase 2 Clinical | Bayer AG | Solid tumours; Stomach Neoplasms | Details |
| Axitinib Implant（Aerie） | AR-14034 SR; AR-14034 | Phase 2 Clinical | Aerie Pharmaceuticals Inc | Macular Degeneration | Details |
| Sorafenib Tosylate/Comekibart | MG-D-1609 | Phase 2 Clinical | Metagone Biotech Inc | Solid tumours | Details |
| KHK-4951 | Phase 2 Clinical | Kyowa Kirin | Macular Edema; Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration | Details | |
| Axitinib injectable suspension (Clearside Biomedical) | CLS-1002; CLS-011-A; CLS011A; CLS-AX | Phase 2 Clinical | Clearside Biomedical Inc | Macular Degeneration | Details |
| nintedanib (Avalyn Pharma) | Phase 1 Clinical | Avalyn Pharma Inc | Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis | Details | |
| Tafetinib Malate | SIM-0702; SIM-1005; SIM-010603 | Phase 1 Clinical | Jiangsu Simcere Pharmaceutical Co Ltd, Nanjing Yoko Biomedical Co Ltd, Jilin Boda Pharmaceutical Co Ltd | Neoplasms | Details |
| DPH-001 | DPH-001; DPH001 | Phase 1 Clinical | Disruptive Pharma AB | Details | |
| MNKD-201 | MNKD-201; MKND-201 | Phase 1 Clinical | MannKind Corp | Idiopathic Pulmonary Fibrosis | Details |
| Inhaled Nintedanib – dry powder (Avalyn Pharma) | AP02; AP 02 DP; AP-02; AP02-DP | Phase 1 Clinical | Avalyn Pharma Inc | Idiopathic Pulmonary Fibrosis; Respiratory Tract Diseases; Lung Diseases, Interstitial; Pulmonary Fibrosis | Details |
| RP-904 | Phase 1 Clinical | Risen (Suzhou) Pharma Tech Co Ltd | Solid tumours | Details | |
| EVT-801 | EVT-801 | Phase 1 Clinical | Sanofi Sa (Sanofi Ag) | Solid tumours | Details |
| Sorafenib tosylate (Bio-Synectics) | BS-104 | Clinical | Bio-Synectics Inc | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Anlotinib Dihydrochloride | AL-3818 | Approved | Advenchen Laboratories Llc, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 福可维 | Mainland China | Carcinoma, Non-Small-Cell Lung | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 2018-05-08 | Sarcoma, Alveolar Soft Part; Peritoneal Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Gastrointestinal Stromal Tumors; Hepatic Insufficiency; Bone Neoplasms; Endometrial Neoplasms; Gallbladder Neoplasms; Fallopian Tube Neoplasms; Thyroid Neoplasms; Medullary thyroid cancer (MTC); Glioma; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Melanoma; Osteoma; Gastroenteropancreatic neuroendocrine tumor; Small Cell Lung Carcinoma; Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Leiomyosarcoma; Esophageal Neoplasms; Stomach Neoplasms; Thoracic Neoplasms; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Biliary Tract Neoplasms; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Neuroendocrine Tumors; Sarcoma, Synovial; Lung Diseases, Interstitial; Liver Diseases; Sarcoma; Bile Duct Diseases; Nasopharyngeal Carcinoma | Details |
| Lenvatinib Mesylate | MK-7902; ER-203492-00; E-7080 | Approved | Eisai Co Ltd | Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 | United States | Thyroid Neoplasms | Eisai Inc | 2015-02-13 | Neuroendocrine Tumors; Paraganglioma; Thyroid Cancer, Papillary; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Glioma; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Breast Neoplasms; Cholangiocarcinoma; Osteosarcoma; Solid tumours; Carcinoma, Adenoid Cystic; Adenocarcinoma, Follicular; Liver Diseases; Thyroid Carcinoma, Anaplastic; Adenocarcinoma of Lung; Neoplasms; Renal Insufficiency; Pheochromocytoma; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Liver Neoplasms; Biliary Tract Neoplasms | Details |
| Axitinib | PF-01367866; AG-13736; AG-013736 | Approved | Pfizer Inc | 英立达, Inlyta | United States | Carcinoma, Renal Cell | Pf Prism Cv | 2012-01-27 | Lung Neoplasms; Carcinoma, Ductal; Uveal melanoma; Breast Neoplasms; Sarcoma; Prostatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Hepatic Insufficiency; Thyroid Neoplasms; Prostatic Neoplasms, Castration-Resistant; Leukemia, Myeloid, Acute; Lymphoma; Carcinoma, Pancreatic Ductal; Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Paraganglioma; Nasopharyngeal Neoplasms; Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Carcinoid Tumor; Pheochromocytoma; Carcinoma; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Kidney Neoplasms; Adrenal Cortex Neoplasms; Skin Neoplasms; Myelodysplastic Syndromes; Glioblastoma; Pancreatic Neoplasms; Mesothelioma; Neuroendocrine Tumors; Carcinoma, Adenoid Cystic | Details |
| Regorafenib | DAST; BAY-73-4506 | Approved | Bayer AG | Stivarga, Resihance | United States | Colorectal Neoplasms | Bayer Healthcare Pharmaceuticals Inc | 2012-09-27 | Leukemia, Myeloid, Acute; Sarcoma, Ewing; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Bone Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Esophageal adenocarcinoma; Lung Neoplasms; Thyroid Neoplasms; Fallopian Tube Neoplasms; Osteosarcoma; Thymoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Neoplasm Metastasis; Adenocarcinoma; Somatostatinoma; Gastrointestinal Neoplasms; Melanoma; Meningioma; Neoplasms; Solid tumours; Liver Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Insulinoma; Carcinoma, Islet Cell; Hemangiosarcoma; Rectal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Adenoma; Glucagonoma; Carcinoma, Adenoid Cystic; Gastrinoma; Sarcoma | Details |
| Nintedanib Esylate | BIBF-1120 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Ofev, Vargatef | United States | Idiopathic Pulmonary Fibrosis | Boehringer Ingelheim Gmbh | 2014-10-15 | Astrocytoma; Sarcoma; Prostatic Neoplasms; Breast Neoplasms; systemic sclerosis-associated interstitial lung disease; Adenocarcinoma, Clear Cell; Peritoneal Neoplasms; Colorectal Neoplasms; Silicosis; Genital Neoplasms, Female; Hepatic Insufficiency; Oligodendroglioma; Gliosarcoma; Uterine Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute; Appendiceal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Glioblastoma; Solid tumours; Telangiectasia, Hereditary Hemorrhagic; Carcinoma, Renal Cell; Endometrial Stromal Tumors; Carcinoid Tumor; Radiation Pneumonitis; Esophageal Neoplasms; Rejection of lung transplantation; Idiopathic Pulmonary Fibrosis; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Colonic Neoplasms; Scleroderma, Systemic; Lung Diseases, Interstitial; Pulmonary Fibrosis; Mesothelioma; Multiple Myeloma; Asbestosis; Neuroendocrine Tumors | Details |
| Tivozanib | KRN-951; KHK-4951; KHK4951; UNII-172030934T; ASP-4130; Kil-8951; AV-951 | Approved | Kyowa Hakko Kirin Co Ltd | Fotivda, FOTIVDA | EU | Carcinoma, Renal Cell | Recordati Netherlands BV | 2017-08-24 | Cholangiocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Metastatic breast cancer; Fallopian Tube Neoplasms; Bile Duct Neoplasms; Hepatic Insufficiency; Peritoneal Neoplasms; Colorectal Neoplasms; Solid tumours; Sarcoma; Wet Macular Degeneration; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Carcinoma, Renal Cell; Biliary Tract Neoplasms; Ovarian Neoplasms | Details |
| Selpercatinib | ARRY-192; Ret-IN-1; LOXO-292; LY-3527723 | Approved | Array Biopharma | Retevmo, Retsevmo | United States | Medullary thyroid cancer (MTC); Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms | Loxo Oncology Inc | 2020-05-08 | Medullary thyroid cancer (MTC); Neuroectodermal Tumors, Primitive, Peripheral; Neoplasms, Germ Cell and Embryonal; Thyroid Cancer, Papillary; Carcinoma, Non-Small-Cell Lung; Glioma; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Thyroid Neoplasms; Hepatic Insufficiency; Neuroblastoma; Histiocytosis, Langerhans-Cell; Sarcoma, Ewing; Osteosarcoma; Fibrosarcoma; Sarcoma; Myofibromatosis; Wilms Tumor; Neoplasms; Thyroid Carcinoma, Anaplastic; Colonic Neoplasms; Hepatoblastoma; Rhabdoid Tumor; Renal Insufficiency; Medulloblastoma; Ependymoma; Rhabdomyosarcoma; Hematologic Neoplasms; Solid tumours | Details |
| Sunitinib Malate | PNU-290940AD; PHA-290940AD; SCAI-003; SU-010398; SU-11248; GB-102; PHA-290940; PNU-290940; SU-011248-L-malate salt | Approved | Pfizer Inc | Sutent, 索坦 | United States | Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell | Cppi Cv | 2006-01-26 | Kidney Neoplasms; Skin Melanoma; Teratoma; Liver Neoplasms; Ovarian Neoplasms; Ependymoma; Head and Neck Neoplasms; Lymphoma, T-Cell, Peripheral; Solid tumours; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic; Leiomyosarcoma; Lymphoma, B-Cell; HIV Infections; Fibrosarcoma; Intestinal Neoplasms; Fibromatosis, Aggressive; Leukemia; Lymphoma, B-Cell, Marginal Zone; Carcinoma, Renal Cell; Pheochromocytoma; Stomach Neoplasms; Abdominal Neoplasms; Pelvic Neoplasms; Polycythemia Vera; Thoracic Neoplasms; Esophageal Neoplasms; Carcinoma, Islet Cell; Carcinoma; Histiocytoma, Malignant Fibrous; Hemangioblastoma; Squamous Cell Carcinoma of Head and Neck; Leukemia, Hairy Cell; Nose Neoplasms; Hypopharyngeal Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic neuroendocrine tumors (pNET); Plasmacytoma; Neoplasms; Pancreatic Neoplasms; Glioblastoma; Lymphoma, Large B-Cell, Diffuse; Lymphomatoid Granulomatosis; Lymphoma, Large-Cell, Immunoblastic; Myelodysplastic Syndromes; Carcinoma, Transitional Cell | Details |
| Pazopanib Hydrochloride | GSK-786034; GW-786034B; SB-786034; GW-786034 | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | 维全特, Armala, Votrient, Patorma | United States | Carcinoma, Renal Cell; Sarcoma | Novartis Pharma Ag | 2009-10-19 | Osteosarcoma; Germinoma; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Colorectal Neoplasms; Uterine Cervical Diseases; Genital Neoplasms, Female; Gliosarcoma; Gastrointestinal Stromal Tumors; Peritoneal Neoplasms; Chondrosarcoma, Extraskeletal Myxoid; Lung Neoplasms; Nasopharyngeal Carcinoma; Medullary thyroid cancer (MTC); Brain Neoplasms; Urethral Neoplasms; Psoriasis; Gastrinoma; Neuroblastoma; Prostatic Neoplasms; Breast Neoplasms; Neoplasms, Germ Cell and Embryonal; von Hippel-Lindau Disease; Thyroid Cancer, Papillary; Neoplasm Metastasis; Breast Neoplasms, Male; Uterine Cervical Neoplasms; Endodermal Sinus Tumor; Paraganglioma; Melanoma; Macular Degeneration; Carcinoma, Hepatocellular; Sarcoma; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Choriocarcinoma; Uterine Neoplasms; Lymphoma; Carcinoma, Neuroendocrine; Glioma; Carcinoma, Embryonal; Skin Melanoma; Neoplasms; Herpes Genitalis; Hemangiosarcoma; Squamous Cell Carcinoma of Head and Neck; Insulinoma; Pheochromo | Details |
| Chloropyramine Hydrochloride | C9; C10; C9A; Y15; CFAK-C4; CFAK-C9; CFAK-C10; CFAK-Y15; CFAK-C9a | Approved | Synopen, Supralgon, Suprastin | Rhinitis, Allergic; Conjunctivitis, Allergic; Asthma | Details | |||||
| Cabozantinib S-malate | XL-184; BMS-907351; RO7047650; RO-7047650 | Approved | Exelixis Inc | Cometriq, Cabometyx | United States | Thyroid Neoplasms; Carcinoma, Neuroendocrine | Exelixis Inc | 2012-11-29 | Neuroblastoma; Thyroid Neoplasms; Hepatic Insufficiency; Astrocytoma; Peritoneal Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Gliosarcoma; Urethral Neoplasms; Sarcoma, Clear Cell; Uterine Neoplasms; Cholangiocarcinoma; Neurofibroma, Plexiform; Brain Neoplasms; Adenocarcinoma, Clear Cell; Carcinoma, Adenosquamous; Medullary thyroid cancer (MTC); Sarcoma, Ewing; Sarcoma; Osteosarcoma; Sarcoma, Alveolar Soft Part; Meningioma; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Endometrioid; Thyroid Cancer, Papillary; Paraganglioma; Neoplasms, Germ Cell and Embryonal; Carcinoma, Hepatocellular; Prostatic Neoplasms; Glioma; Brain metastases; Endometrial Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Lymphoma; Carcinoma, Neuroendocrine; Fallopian Tube Neoplasms; Carcinoma, Renal Cell; Adenoma, Islet Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Renal Insufficiency; Hepatoblastoma; Pheochromocytoma; Carcinoid Tumor; Carcinoma, Merkel Cell; Rejection of liver transp | Details |
| Fruquintinib | HMPL-013; TAK-113 | Approved | Hutchison Medipharma Ltd | FRUZAQLA, Aiyoute, 爱优特, Elunate | Mainland China | Colorectal Neoplasms | Hutchison Medipharma Ltd | 2018-09-04 | Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Metastatic breast cancer; Endometrial Neoplasms; Hepatic Insufficiency; Colorectal Neoplasms; Breast Neoplasms; Sarcoma; Neoplasms; Solid tumours; Colonic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Renal Cell; Rectal Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Renal Insufficiency; Biliary Tract Neoplasms | Details |
| Sorafenib Tosylate | NSC-724772; BAY-43-0006; BAY-43-9006; BAY-54-9085 | Approved | Onyx Pharmaceuticals Inc | Nexavar, 多吉美 | United States | Carcinoma, Renal Cell | Bayer Healthcare Pharmaceuticals Inc | 2005-12-01 | Liver Neoplasms; Leukemia, Myelogenous, Chronic; Leiomyosarcoma; Rhabdomyosarcoma; Solid tumours; Ovarian Neoplasms; Fibromatosis, Aggressive; Kidney Neoplasms; Leukemia, Myeloid; Head and Neck Neoplasms; Skin Melanoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, T-Cell, Peripheral; Leukemia, Erythroblastic, Acute; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Histiocytoma, Malignant Fibrous; Stomach Neoplasms; Rectal Neoplasms; Carcinoma, Islet Cell; Insulinoma; Esophageal Neoplasms; Vipoma; Hemangiosarcoma; Abdominal Neoplasms; Wilms Tumor; Hypertension, Portal; Thyroid Carcinoma, Anaplastic; Neoplasms; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Leukemia, Myelomonocytic, Acute; Lymphomatoid Granulomatosis; Carcinoma, Transitional Cell; Colonic Neoplasms; Salivary Gland Neoplasms; Lymphoma, Large B-Cell, Diffuse; Multiple Endocrine Neoplasia Type 2a; Lymphoma, Large-Cell, Immunoblastic; Leukemia-Lymphoma, Adu | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland